Literature DB >> 15677569

Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation.

Yasodha Natkunam1, Izidore S Lossos, Behnaz Taidi, Shuchun Zhao, XiaoQing Lu, Feying Ding, Anne Sofie Hammer, Teresa Marafioti, Gerald E Byrne, Shoshana Levy, Roger A Warnke, Ronald Levy.   

Abstract

We identified the human germinal center-associated lymphoma (HGAL) in gene-expression profiling studies of diffuse large B-cell lymphoma (DLBCL). The expression of HGAL correlated with survival in patients with DLBCL. The HGAL gene is the human homolog of M17, a mouse gene expressed specifically in normal germinal center (GC) B cells. We generated a monoclonal antibody against the HGAL protein and show that HGAL is expressed in the cytoplasm of GC lymphocytes and in lymphomas of GC derivation. Among 727 lymphomas tested by immunohistochemistry on tissue microarrays, HGAL staining was found in follicular lymphomas (103 of 107), Burkitt lymphomas (40 of 40), mediastinal large B lymphomas (7 of 8), and in DLBCLs (103 of 151). Most marginal zone lymphomas lacked HGAL staining. Lymphocyte-predominant Hodgkin lymphomas (12 of 17) and, surprisingly, classical Hodgkin lymphomas (78 of 107) were found to be positive. Hierarchical clustering of comparative immunohistologic results in DLBCLs demonstrates that the expression of HGAL is similar to 2 other GC-associated proteins, BCL6 and CD10, but different from 2 markers associated with a non-GC phenotype, MUM1/IRF4 and BCL2. The restricted expression and GC specificity of HGAL protein suggest that it may have an important role in the diagnosis of specific lymphomas, and, potentially in the identification of subtypes associated with different prognoses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15677569      PMCID: PMC1895083          DOI: 10.1182/blood-2004-08-3112

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.

Authors:  Margaret A Shipp; Ken N Ross; Pablo Tamayo; Andrew P Weng; Jeffery L Kutok; Ricardo C T Aguiar; Michelle Gaasenbeek; Michael Angelo; Michael Reich; Geraldine S Pinkus; Tane S Ray; Margaret A Koval; Kim W Last; Andrew Norton; T Andrew Lister; Jill Mesirov; Donna S Neuberg; Eric S Lander; Jon C Aster; Todd R Golub
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

2.  Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes.

Authors:  A Conconi; F Bertoni; E Pedrinis; T Motta; E Roggero; S Luminari; C Capella; M Bonato; F Cavalli; E Zucca
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

3.  Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays.

Authors:  Chih Long Liu; Wijan Prapong; Yasodha Natkunam; Ash Alizadeh; Kelli Montgomery; C Blake Gilks; Matt van de Rijn
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 4.  Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry.

Authors:  Brunangelo Falini; David Y Mason
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

5.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

6.  Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.

Authors:  Sharon L Barrans; Ian Carter; Roger G Owen; Faith E Davies; Russell D Patmore; Andrew P Haynes; Gareth J Morgan; Andrew S Jack
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

7.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

Authors:  Kerry J Savage; Stefano Monti; Jeffery L Kutok; Giorgio Cattoretti; Donna Neuberg; Laurence De Leval; Paul Kurtin; Paola Dal Cin; Christine Ladd; Friedrich Feuerhake; Ricardo C T Aguiar; Sigui Li; Gilles Salles; Francoise Berger; Wen Jing; Geraldine S Pinkus; Thomas Habermann; Riccardo Dalla-Favera; Nancy Lee Harris; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

8.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

9.  Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.

Authors:  Lluís Colomo; Armando López-Guillermo; María Perales; Susana Rives; Antonio Martínez; Francesc Bosch; Dolors Colomer; Brunangelo Falini; Emili Montserrat; Elías Campo
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

10.  HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.

Authors:  Izidore S Lossos; Ash A Alizadeh; Ranjani Rajapaksa; Robert Tibshirani; Ronald Levy
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113

View more
  44 in total

1.  HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway.

Authors:  Xiaoyu Jiang; Xiaoqing Lu; George McNamara; Xiaofei Liu; Elena Cubedo; Kristopher A Sarosiek; Isidro Sánchez-García; David M Helfman; Izidore S Lossos
Journal:  Blood       Date:  2010-09-15       Impact factor: 22.113

2.  M17, a gene specific for germinal center (GC) B cells and a prognostic marker for GC B-cell lymphomas, is dispensable for the GC reaction in mice.

Authors:  Dominik Schenten; Angela Egert; Manolis Pasparakis; Klaus Rajewsky
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

3.  Interplay between HGAL and Grb2 proteins regulates B-cell receptor signaling.

Authors:  Xiaoyu Jiang; Xiaoqing Lu; Yu Zhang; Leda Lacaria; Brett J Schuchardt; David C Mikles; Marco Magistri; Idoia García-Ramírez; Isidro Sanchez-Garcia; Amjad Farooq; Ramiro E Verdun; Midhat H Abdulreda; Vincent T Moy; Izidore S Lossos
Journal:  Blood Adv       Date:  2019-08-13

Review 4.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

5.  C-MYC rearrangements are frequent in aggressive mature B-Cell lymphoma with atypical morphology.

Authors:  Xianfeng F Zhao; Anjum Hassan; Arie Perry; Yi Ning; Sanford A Stass; Louis P Dehner
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

6.  Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma--combined performance of multiple markers.

Authors:  Michiel van den Brand; Janneke J M Mathijssen; Mar Garcia-Garcia; Konnie M Hebeda; Patricia J T A Groenen; Brunangelo Falini; Sergio Serrano; J Han J M van Krieken
Journal:  Haematologica       Date:  2015-06-11       Impact factor: 9.941

7.  CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas.

Authors:  Robert F Luo; Shuchun Zhao; Robert Tibshirani; June H Myklebust; Mrinmoy Sanyal; Rosemary Fernandez; Dita Gratzinger; Robert J Marinelli; Zhi Shun Lu; Anna Wong; Ronald Levy; Shoshana Levy; Yasodha Natkunam
Journal:  Hum Pathol       Date:  2009-12-08       Impact factor: 3.466

8.  HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration.

Authors:  Xiaoqing Lu; Jun Chen; Raquel Malumbres; Elena Cubedo Gil; David M Helfman; Izidore S Lossos
Journal:  Blood       Date:  2007-09-06       Impact factor: 22.113

Review 9.  LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.

Authors:  Chen Lossos; Soley Bayraktar; Elizabeth Weinzierl; Sheren F Younes; Peter J Hosein; Robert J Tibshirani; Jocelyn Sutton Posthumus; Lisa M DeAngelis; Jeffrey Raizer; David Schiff; Lauren Abrey; Yasodha Natkunam; Izidore S Lossos
Journal:  Br J Haematol       Date:  2014-02-26       Impact factor: 6.998

10.  Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes.

Authors:  Ryan A Metcalf; Shuchun Zhao; Matthew W Anderson; Zhi Shun Lu; Ilana Galperin; Robert J Marinelli; Athena M Cherry; Izidore S Lossos; Yasodha Natkunam
Journal:  Mod Pathol       Date:  2010-01-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.